Accelerating Outpatient Proof-of-Concept Based on Medical Concierge Services

Wearable AI diagnostic monitoring company Cears announced on the 29th that its wearable electrocardiogram (ECG) device, mobiCARE™, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).


This clearance means more than just the completion of regulatory procedures for U.S. sales; it is also significant in that it has accelerated the U.S. business roadmap Cears has been pursuing, ahead of expectations. The company had anticipated obtaining clearance in the third quarter of this year after submitting the final FDA 510(k) documents last month, but secured approval at the end of June, establishing an early foundation for its entry into the U.S. market.

Cears' mobiCARE Receives FDA 510(k) Clearance, Signaling Green Light for Global Expansion View original image

Accordingly, Cears can proceed with its ECG testing service based on U.S. medical concierge infrastructure faster than initially planned. The company has been implementing a strategy to enter the Medicare reimbursement market by collaborating with local medical institutions to conduct outpatient proof-of-concept (PoC) studies. With the early FDA clearance, the schedule for outpatient PoC studies can also be advanced, and the timing for obtaining Medicare reimbursement and commercializing the service is expected to progress without any setbacks.


The United States is one of the world's largest arrhythmia diagnosis markets. More than 14 million arrhythmia diagnostic tests are conducted annually, and the Medicare-based ECG reimbursement rate is about $250 per test—approximately five times higher than the domestic reimbursement rate, making it a high value-added market. With the aging population and increasing prevalence of cardiovascular diseases, demand for wearable long-term ECG monitoring is rapidly expanding, leading to high expectations for the growth potential of the digital healthcare market that combines AI-based analysis services.


This FDA clearance is expected to have a positive impact not only on the U.S. market but also on the expansion of global business. As the FDA is considered one of the most credible medical device regulatory authorities worldwide, its approval can serve as an important reference in future product clearances and business negotiations in overseas markets such as the Middle East and Asia. Following the recent supply agreement in the UAE and now the acquisition of FDA clearance, the company anticipates increased momentum for its global business expansion.


Cears has already proven its business performance in the domestic hospital market through its AI medical platform, thynC™, and now plans to foster the U.S. and Middle East as its two main global growth axes with mobiCARE™. Based on the clinical data, AI analysis technology, and hospital operation experience accumulated in the domestic market, the company aims to become a global AI medical platform company focusing on the U.S. Medicare market and GCC countries.



Lee Youngshin, CEO of Cears, stated, "With this FDA clearance, the AI ECG analysis platform that has proven its business potential in Korea can now be validated in the U.S. market as well. We will steadily push ahead with outpatient PoC studies and entry into the Medicare market in the U.S., and gradually expand our global business based on this foundation."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing